Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myobloc.

Timothy Corcoran Flynn1

  • 1Department of Dermatology, University of North Carolina, Chapel Hill, NC 27514, USA. flynn@caryskincenter.com

Dermatologic Clinics
|June 30, 2004
PubMed
Summary
This summary is machine-generated.

Myobloc, a type B botulinum toxin, targets synaptobrevin, unlike type A toxins that target SNAP-25. This review explores Myobloc

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrastructural analysis of 3 hyaluronic acid soft-tissue fillers using scanning electron microscopy.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2015
Same author

Molecular weight analyses and enzymatic degradation profiles of the soft-tissue fillers Belotero Balance, Restylane, and Juvéderm Ultra.

Plastic and reconstructive surgery·2013
Same author

IncobotulinumtoxinA in esthetics.

Journal of drugs in dermatology : JDD·2013
Same author

Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2012
Same author

Advances in the use of botulinum neurotoxins in facial esthetics.

Journal of cosmetic dermatology·2012
Same author

Comparative histology of intradermal implantation of mono and biphasic hyaluronic acid fillers.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2011

Area of Science:

  • Neuroscience
  • Pharmacology
  • Dermatology

Background:

  • Myobloc is the sole commercial type B botulinum toxin approved in the US for cervical dystonia.
  • Type A botulinum toxins (Botox, Dysport) are more common and target SNAP-25.
  • Type B botulinum toxin (Myobloc) targets vesicle-associated membrane protein (synaptobrevin).

Purpose of the Study:

  • To elucidate the distinctions between Myobloc (type B) and commonly used type A botulinum toxins.
  • To review existing literature on Myobloc's efficacy, including equivalency studies.
  • To explore the application of Myobloc in facial aesthetic procedures.

Main Methods:

  • Comparative analysis of botulinum toxin mechanisms of action.
  • Literature review of published studies on Myobloc and type A toxins.

Related Experiment Videos

  • Discussion of clinical applications in aesthetic medicine.

    • Main Results:

    • Type B and type A botulinum toxins exhibit distinct antigenic properties.
    • Myobloc acts on synaptobrevin, while type A toxins act on SNAP-25.
    • Evidence supports Myobloc's utility in specific aesthetic contexts.

    Conclusions:

    • Myobloc offers a distinct therapeutic option from type A toxins due to its unique protein target and antigenic profile.
    • Further research and clinical studies can expand the understanding of Myobloc's role in aesthetic treatments.
    • Understanding these differences is crucial for appropriate clinical selection and application.